Clark C, Lewczuk P, Kornhuber J, Richiardi J, Maréchal B, Karikari TK, Blennow K, Zetterberg H, Popp J (2021)
Publication Type: Journal article
Publication year: 2021
Book Volume: 13
Article Number: 65
Journal Issue: 1
DOI: 10.1186/s13195-021-00805-8
Background: To assess the performance of plasma neurofilament light (NfL) and phosphorylated tau 181 (p-tau181) to inform about cerebral Alzheimer’s disease (AD) pathology and predict clinical progression in a memory clinic setting. Methods: Plasma NfL and p-tau181, along with established cerebrospinal fluid (CSF) biomarkers of AD pathology, were measured in participants with normal cognition (CN) and memory clinic patients with cognitive impairment (mild cognitive impairment and dementia, CI). Clinical and neuropsychological assessments were performed at inclusion and follow-up visits at 18 and 36 months. Multivariate analysis assessed associations of plasma NfL and p-tau181 levels with AD, single CSF biomarkers, hippocampal volume, and clinical measures of disease progression. Results: Plasma NfL levels were higher in CN participants with an AD CSF profile (defined by a CSF p-tau181/Aβ
APA:
Clark, C., Lewczuk, P., Kornhuber, J., Richiardi, J., Maréchal, B., Karikari, T.K.,... Popp, J. (2021). Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer’s disease pathology and clinical disease progression. Alzheimer's Research and Therapy, 13(1). https://doi.org/10.1186/s13195-021-00805-8
MLA:
Clark, Christopher, et al. "Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer’s disease pathology and clinical disease progression." Alzheimer's Research and Therapy 13.1 (2021).
BibTeX: Download